casopitant
Selected indexed studies
- Casopitant: a new warrior in the antiemetic crusade. (Expert Opin Pharmacother, 2009) [PMID:19445564]
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. (Cochrane Database Syst Rev, 2020) [PMID:33075160]
- Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. (Curr Opin Investig Drugs, 2008) [PMID:18600583]
_Worker-drafted node — pending editorial review._
Connections
casopitant is a side effect of
Sources
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. (2020) pubmed
- Casopitant: a new warrior in the antiemetic crusade. (2009) pubmed
- Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. (2008) pubmed
- Why no casopitant-only arm? (2011) pubmed
- Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. (2011) pubmed
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. (2021) pubmed
- The evaluation of drug rechallenge: the casopitant Phase III program. (2010) pubmed
- Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. (2009) pubmed
- Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. (2009) pubmed
- Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4. (2011) pubmed